Clinical Trial Update: A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating tabelecleucel in EBV-associated diseases is active/not recruiting, focusing on EBV+ LPD and related conditions.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allogeneic Hematopoietic Cell Transplant
• Ebv Lymphoproliferative Disease with Acquired Immunodeficiency
• Ebv Lymphoproliferative Disease with Primary Immunodeficiency
• Ebv Post-transplant Lymphoproliferative Disease
• Ebv Posttransplant Lymphoproliferative Disease in Central Nervous System
• Ebv Sarcomas
• Epstein-barr Virus -associated Diseases
• Leiomyosarcoma
• Lymphoproliferative Disorders
• Solid Organ Transplant Complications
• Stem Cell Transplant Complications

Drugs mentioned

• Tabelecleucel (tabelecleucel)

Snippet

Sponsor: Pierre Fabre Medicament | Conditions: Epstein-Barr Virus (EBV)-Associated Diseases, EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD) | Phase 2 | Status: ACTIVE_NOT_RECRUITING